Skip to content
Servier
-
Servier to acquire Edgewise’s muscular dystrophy unit in US$2.65B precision medicine deal
Under the agreement, Servier will take control of Edgewise Therapeutics’ muscular dystrophy portfolio, including its lead candidate sevasemten.